Corbevax and Covovax, and the anti-viral drug molnupiravir can only be used in an emergency
New Delhi:
The Center today approved two more vaccines and an anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines approved by India are Corbevax and Covovax. The anti-viral drug molanupiravir can be used in an emergency.
-
Corbevax is India’s first domestic “RBD protein sub-unit vaccine”, tweeted Health Minister Mansukh Mandaviya this morning. It has been made by Hyderabad-based firm Biological-E.
-
“It’s a hat-trick! Now this is the third vaccine to be developed in India,” said Mr. Mandaviya. The other two vaccines developed in India are Bharat Biotech’s Covaxin and Serum Institute of India’s (SII) Covishield.
-
The nanoparticle vaccine, Kovovax, will be manufactured by Pune-based SII.
-
The health minister said the anti-viral drug mollupiravir will be manufactured by 13 companies in India for restricted use in emergency situations to treat adult patients with COVID-19 who are at high risk of developing the disease. Is.
-
With the latest approvals, a total of eight COVID-19 vaccines have received emergency use authorization from India’s drug regulator – Covisheeld, Covaxin, ZyCoV-D, Sputnik V, Moderna, Johnson and Johnson, Corbevax and Covovax.
-
Dr Reddy’s Laboratories along with Cipla, Mylan, Torrent, Emcure and Sun Pharma had submitted their proposal for approval of the anti-viral drug Molnupiravir for emergency situations.
-
The US Food and Drug Administration recently approved Merck’s mollupiravir to treat mild to moderate COVID-19 cases in adults who are at risk of severe disease. Earlier in November, Britain granted conditional authorization to Merck’s coronavirus antiviral, the first pill shown to successfully treat COVID-19.
-
In a clinical trial of people at high risk in the early stages of the disease, Merck’s drug was shown to reduce hospitalizations and deaths by about 30 percent.
-
India will start giving COVID-19 booster shots to healthcare, frontline workers and people above 60 with comorbidities from January 10. People aged 15-18 will start getting their COVID-19 vaccination from January 3.
-
The emergence of the highly permeable Omicron variant has plunged the world into a renewed battle against COVID-19. In India, Delhi and other states have announced night curfews around this time to prevent crowding in public places during the new year.
,